Neuroblastoma (NB) is the most common extracranial malignant solid tumor seen in children and continues to lead to the death of many pediatric cancer patients. The poor outcome in high risk NB is largely attributed to the development of chemoresistant tumor cells. Doxorubicin (dox) has been widely employed as a potent anti-cancer agent in chemotherapeutic regimens; however, it also leads to chemoresistance in many cancer types including NB. Thus, developing novel small molecules that can overcome dox-induced chemoresistance is a promising strategy in cancer therapy. Here we show that the second generation proteasome inhibitor ixazomib (MLN9708) not only inhibits NB cell proliferation and induces apoptosis in vitro but also enhances dox-induced cytotoxicity in NB cells. Ixazomib inhibits dox-induced NF-κB activity and sensitizes NB cells to dox-induced apoptosis. More importantly, ixazomib demonstrated potent anti-tumor efficacy in vivo by enhancing dox-induced apoptosis in an orthotopic xenograft NB mouse model. Collectively, our study illustrates the anti-tumor efficacy of ixazomib in NB both alone and in combination with dox, suggesting that combination therapy including ixazomib with traditional therapeutic agents such as dox is a viable strategy that may achieve better outcomes for NB patients.
cytoplasm in an inactive state 13 . NF-κ B is known for its central role in immune responses, but it also facilitates chemoresistance and progression of tumors when activated in the presence of most chemotherapeutic agents, including dox [14] [15] [16] . Dox-induced NF-κ B activation is believed to contribute to the development of chemoresistance of cancer cells exposed to dox treatment [17] [18] [19] . Thus, inhibiting NF-κ B activity to overcome chemoresistance may be a viable option in cancer therapy.
Ixazomib (MLN9708, trade name Ninlaro), a selective and orally active second-generation proteasome inhibitor, was developed to treat a broad range of cancers 20 and exhibits anti-tumor efficacy in multiple malignancies [21] [22] [23] . To date, the anti-tumor efficacy of ixazomib in NB has yet to be investigated. Here we report that ixazomib suppresses NB cell proliferation and anchorage-independent growth and induces cell apoptosis. Furthermore, in NB cells, including the chemoresistant LA-N-6 cell line, ixazomib synergizes with dox treatment by enhancing the cytotoxicity of dox and overcoming dox resistance by stabilizing the Iκ Bα protein and inhibiting dox-induced NF-κ B activation. More importantly, ixazomib potently enhanced dox-induced apoptosis in an orthotopic xenograft NB mouse model. Overall, our study displays the anti-tumor efficacy of ixazomib alone and in combination with dox in NB, illustrating that combination therapy of ixazomib and dox may lead to better outcomes for NB patients.
Results
Ixazomib shows cytotoxic effect on a subset of NB cell lines. To assess the potential cytotoxic effect of ixazomib on NB cells, six human NB cell lines (IMR-32, NGP, NB-19, SH-SY5Y, SK-N-AS and the chemoresistant LA-N-6 cell line) were treated with increasing doses of ixazomib. After 72 hrs of exposure to the inhibitor, the viabilities of the cells were measured. As shown in Fig. 1a , ixazomib suppressed the cell viability of all six NB cell lines tested in a dose-dependent manner. The IC50s of ixazomib in the six NB cells lines were calculated according to the data collected in the cell viability assay (Fig. 1b) . Moreover, the cytotoxic effect of ixazomib on the NB cells was further confirmed by cell morphology changes upon treatment (Fig. 1c) . Ixazomib attenuates the colony formation ability of NB cells. The ability to form colonies in soft agar cultures is one of the defining properties of cancer cells and is frequently used to evaluate the anchorage-independent growth of the cells. To determine whether ixazomib affects the colony formation ability of the NB cell lines, soft agar assays were performed with two concentrations of the inhibitor. As shown in Fig. 2a , ixazomib significantly suppressed the ability of the four chosen NB cell lines to form colonies compared with the control, untreated cells. Colony numbers in the agar were quantified in each group, and we found that ixazomib attenuates the colony formation ability of the tested NB cell lines in a dose dependent manner (Fig. 2b ). These results demonstrate that ixazomib significantly inhibits the anchorage-independent growth of a panel of NB cell lines.
Ixazomib induces apoptosis in most of NB cells. Ixazomib has been reported to induce apoptosis in chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) as a single agent or in combination with other chemotherapeutic agents 21, 24 . Thus, we hypothesized that ixazomib may induce apoptosis in NB cells. To test our hypothesis, IMR-32, NGP, NB-19, SH-SY5Y, SK-N-AS and LA-N-6 cells were treated with ixazomib at the indicated dose and time points (0-24 hrs). After treatment, cell pellets were collected separately to perform protein immunoblotting assays. As expected, we found that ixazomib induced significant PARP cleavages in IMR-32, SH-SY5Y, and SK-N-AS cells; however, the effect of ixazomib was less significant on NGP and NB-19 cells (Fig. 3a-e) . Similar results of Caspase-3 cleavages were obtained in these cell lines upon ixazomib treatment. However, ixazomib alone had little effect on LA-N-6 cells under the same treatment condition as to other NB cell lines (Fig. 3f) . These data indicate that ixazomib alone induces apoptosis in the five NB cell lines tested except the chemoresistant LA-N-6 cell line in a time dependent manner. , and ixazomib has been shown to induce apoptosis in CLL cells in combination with other agents 24 . Therefore, we hypothesized that inhibition of proteasome activity by ixazomib may increase the chemosensitivity of NB cells to dox. To test our hypothesis, we treated IMR-32, NGP, NB-19, SH-SY5Y, SK-N-AS and LA-N-6 cells with either dox alone or in combination with ixazomib (1 μ M or 5 μ M). As displayed in Fig. 4a -f, the combination of ixazomib with dox shows a greater inhibitory effect on cell proliferation than single agent dox treatment. These results suggest that ixazomib sensitizes a subset of NB cell lines to dox treatment, therefore augmenting the cytotoxic effect of dox in NB cells.
Ixazomib enhances dox-induced apoptosis both in vitro and in vivo.
To determine whether ixazomib could enhance dox-induced apoptosis in NB cells, six NB cell lines were treated with dox alone (1 μ M or 2 μ M or 5 μ M), ixazomib alone (1 μ M or 2 μ M or 5 μ M), or their combination for the indicated time points. The cells were then collected for the immunoblotting assay. Compared with the single agent treatment groups with either dox or ixazomib, the combination group showed stronger PARP and Caspase-3 cleavages in all six of the cell lines tested ( Fig. 5a-f ), suggesting that ixazomib enhances dox-induced apoptosis in NB cells.
To determine the anti-tumor efficacy of ixazomib in vivo, the NGP-luciferase cells xenografted nude mice were treated with dimethyl sulfoxide (DMSO) or dox (1 mg/kg) or ixazomib (2 mg/kg) or their combination by intraperitoneal (i.p.) injection daily for four days. And then the tumors were harvested and lysed for protein immunoblotting. As shown in Fig. 5g , the combination group of dox and ixazomib treatment significantly increased PARP and Caspase-3 cleavages compared with DMSO control group or the single agent treatment groups with either dox or ixazomib, indicating that ixazomib augments dox-induced apoptosis in an orthotopic xenograft NB mouse model. Taken together, ixazomib enhances dox-induced apoptosis both in vitro and in vivo.
Ixazomib enhances dox-induced p38 and JNK activity and decreases dox-induced IκBα degradation. The activation of MAPK members JNK and p38 has been reported to be responsible for dox-induced apoptosis 6, 26, 27 . To determine the mechanism of the enhanced cytotoxic effect of ixazomib on dox treated NB cells, we treated the NB cells with dox (20 μ M) alone or in combination with ixazomib (1 μ M or 5 μ M) at different time points. After performing the protein immunoblotting assay, we found that the combination treatment increased the phosphorylation of p38 and JNK compared to the dox single treatment (Fig. 6a-f ).
Previous studies have also shown that dox treatment in MCF-7 cells caused drug resistance in a NF-κ B dependent manner 28 and that the inhibition of NF-κ B activity could at least partially overcome dox-induced resistance in MCF-7 and human osteosarcoma cell lines 19, 29 . Iκ Bα is known to negatively regulate NF-κ B by blocking the NLS of the NF-κ B protein to keep it sequestered in an inactive state in the cytoplasm 13 . Thus, to determine whether the sensitization effect of ixazomib on dox-induced cytotoxicity results from the inhibition of NF-κ B activity, Iκ Bα protein level was tested. As illustrated in Fig. 6a-f , dox induced Iκ Bα protein degradation whereas ixazomib suppressed dox-induced Iκ Bα protein degradation in all six NB cell lines tested, suggesting that dox-induced NF-κ B activity is inhibited by ixazomib. Taken together, our results support a working model in which ixazomib enhances dox-induced apoptosis by suppressing dox-induced NF-κ B activity (Fig. 7) .
Discussion
Consisting of multiple proteases, the proteasome is an essential component of the ubiquitin-proteasome system, which is responsible for the degradation of intracellular proteins 30 . The high abundance and ubiquitous presence of proteasomes in the cytosol reveals the central role of proteasomes played in the regulation of cell cycle control, apoptosis, cellular stress response, and cell fate determination 31 . Dysfunction of the proteasome is associated with tumor cell survival, and pharmacological inhibition of proteasome activity by small molecule inhibitors shows anti-tumor efficacy in various cancer types [32] [33] [34] [35] [36] . Here we report that the second generation proteasome inhibitor ixazomib exerts its anti-tumor effect in NB by suppressing NB cell proliferation and inducing apoptosis.
As an anthracycline antitumor antibiotic, dox intercalates within the double strands of DNA and causes DNA damage, thus inhibiting the progression of topoisomerase II. This, in turn, relaxes supercoils in DNA for transcription and ultimately results in apoptosis 37 . Dox has been used as an anti-cancer agent for treating a variety of cancer types. However, clinical application of high dose of dox is limited due to its association with multiple damaging side effects, especially injury to the heart 5 . Thus, finding ways to enhance the intended anti-cancer effects of dox is vitally important. In this study, we show that ixazomib significantly enhances the cytotoxicity of dox in NB cells. Moreover, ixazomib augments dox-induced apoptosis by promoting JNK and p38 mediated apoptosis. Chemoresistance has been considered as one of the major causes of relapse in patients, especially in high-risk NB patients. Therefore, clarifying the molecular mechanisms that are responsible for chemoresistance is of vital importance. Activation of the transcription factor NF-κ B has been reported to be a mechanism for chemoresistance and, thus, targeting NF-κ B pathway to overcome chemoresistance may be a viable strategy 38 . The proteasome has been reported to be involved in NF-κ B activation by promoting the degradation of its inhibitor Iκ Bα 39 . Therefore, pharmacological inhibition of proteasome activity results in attenuated dox-induced chemoresistance. We found that ixazomib could overcome dox-induced chemoresistance by stabilizing Iκ Bα expression levels and inactivating NF-κ B in NB cell lines, including the chemoresistance LA-N-6 cell line. Therefore, ixazomib improves the therapeutic index of dox and broadens the spectrum of dox applications.
Due to the critical roles that the proteasome plays in cellular functions, aberrant activation or deactivation of proteasomes may affect a variety of proteins and result in many human diseases, including cancer 40 . The orally active proteasome inhibitor ixazomib has been approved by the FDA for the treatment of patients with multiple myeloma in combination with lenalidomide and dexamethasone 41 . Compared with the first generation proteasome inhibitor bortezomib, ixazomib exhibits better clinical outcomes and reduced toxicities in the treatment of patients with multiple myeloma, due to modified chemical moieties. Therefore, it's likely that ixazomib may achieve better outcome for NB patients.
In summary, our study reveals the anti-tumor efficacy of ixazomib in NB cells. In NB cells, ixazomib exerts potent anti-oncogenic effects not only by inducing apoptosis but also by enhancing the cytotoxicity of dox. Moreover, ixazomib sensitizes NB cells, including the chemoresistant LA-N-6 cells, to dox treatment by stabilizing Iκ Bα and suppressing dox-induced NF-κ B activity. More importantly, ixazomib potently enhanced dox-induced cellular apoptosis of the tumor cells in an orthotopic xenograft NB mouse model. Therefore, it's feasible to initiate clinical trials for the treatment of NB by including ixazomib in combination with current therapeutic agents like 24 hrs) , and the cells were collected, subjected to SDS-PAGE, and immunoblotted with PARP, Caspase-3, and β -actin primary antibodies. (g) The mice bearing NGP xenografted tumors for six weeks were treated as described, and then the tumors were harvested and lysed, subjected to SDS-PAGE and immunoblotted with the indicated antibodies. β -actin was used as a loading control for whole cell extracts in all samples.
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dox. This study supports the idea that combination therapies of proteasome inhibitors with standard chemotherapeutic agents will achieve better outcomes in NB therapy.
Materials and Methods
Antibodies and Reagents. The proteasome inhibitor ixazomib was purchased from APExBIO (A4007) (Houston, TX, USA). Doxorubicin (dox, D1515) and anti-β -Actin (A2228) antibody were purchased from Sigma (Sigma-Aldrich Corp, St. Louis, MO, USA). Anti-PARP (9532S), anti-Caspase-3 (9662S), anti-phospho-SAPK/JNK (Thr183/Tyr185) (9251S), anti-SAPK/JNK (9258S), anti-phospho-p38 MAP kinase (Thr180/Tyr182) (9211S), anti-p38 MAP kinase (8690S), anti-Iκ Bα (9242S), anti-rabbit (7074S) IgG, and anti-mouse (7076S) antibodies were purchased from Cell Signaling Technology (Cell Signaling Technology, Danvers, MA, USA). Colony Formation Assay. The colony formation assay was performed as previously described 42, 43 . To make a 5% (w/v) base agar, agar powder (214220, Difco Laboratories, Detroit, MI, USA) was added to distilled water, and the mixture was autoclaved for 50 min. The mixture was then cooled down in a 56 °C water bath. For the bottom agar layer, each well in the six-well plate was filled with 2 mL of the 0.5% agar/RPMI 1640 (supplemented with 10% FBS) solution, and the solution was cooled until semi-solid. For the top agar layer, 8 × 10 3 pre-counted NB cells per well were mixed with 1.5 ml of 0.3% agar. Indicated concentrations of ixazomib were added to the wells 24 hrs later. Cells were cultured at 37 °C for two to three weeks and then stained with 500 μ L of 0.005% crystal violet (C3886, Sigma). Four hours later, cell images were taken and the colonies were counted by using the VersaDoc Imaging System (Bio-Rad Laboratories, Hercules, CA, USA). All the assays were performed in triplicate, and representative images were shown in the figures.
Cell Lines and Cell
Protein Immunoblotting. The protein immunoblotting assay was performed as described 44, 45 . Cells were collected at the end of the treatments and lysed for 30 min at 4 °C in cooled RIPA buffer (50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 10 μ g/mL leupeptin, 1 mM dithiothreitol, 50 mM sodium fluoride, 0.1 mM sodium orthovanadate, and phosphatase inhibitor cocktail 2 and 3 (p5726 and p0044, Sigma)). The cell lysates were centrifuged at 13,000 rpm for 15 min, and the supernatants were used as loading samples. Protein concentrations of the samples were measured using a Bradford reagent (Bio-Rad Laboratories, Hercules, CA, USA), and each sample was mixed with 4 × loading buffer before heating. The mixture was then heated at 100 °C for 8 min to denature the samples. Then, the samples were separated by SDS-PAGE, transferred to polyvinylidence fluoride (PVDF) membranes (EMD-Milipore, Billerica, MA, USA), blocked with 5% milk for one hour at room temperature (RT, 25 °C), and probed with the suggested dilutions of indicated primary antibodies overnight at 4 °C. Anti-mouse or rabbit secondary antibodies conjugated with horseradish peroxidase were incubated with the membranes at RT for one hour. After that, the signals on the membranes were detected using the ECL-Plus Western Detection System (GE Health Care, Buckinghamshire, UK). β -actin was used as a loading control for whole cell extracts in all groups.
Combinatorial effect of ixazomib and dox in an orthotopic xenograft NB mouse model. Female athymic NCR nude mice of five to six-week-old were purchased from Taconic (Taconic, Hudson, NY, USA) and kept under barrier conditions (pathogen-free conditions provided by plastic cages with sealed air filters). The orthotopic xenograft NB mouse model was established by using orthotopic (intrarenal) implantation of the NB cells as described previously 46, 47 . Briefly, a transverse incision was created over the left flank of the nude mice and 1.5 × 10 6 luciferase-transduced NGP cells in 0.1 ml of PBS were surgically injected into the left renal capsule of the left kidney of the nude mice.
Six weeks after implantation, the NGP-luciferase cells implanted nude mice were treated with DMSO or dox (1 mg/kg) or ixazomib (2 mg/kg) or their combination by i.p. injection daily for four days. At the end of the treatment, the mice were sacrificed and the tumors were harvested and lysed for protein immunoblotting. All mice were handled according to protocols approved by the Institutional Animal Care and Use Committee of the Baylor College of Medicine.
Statistical Analysis. All the presented values were shown as mean ± S.D. A two-tailed Student's t-test was used to determine the statistical significance of all the assays between the control and drug treated groups. A P-value < 0.05 was considered to be statistically significant in all of the assays. Each assay was performed at least twice and the representative results were presented in the figures.
